Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart attack survivors: shorter blood thinner course may be safer and effective

NCT ID NCT07507500

Disease control Sponsor: Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 10, 2026 · Updated 2 times

Summary

This study involves 8,100 adults who had a heart attack and received a stent. It compares different approved blood-thinning strategies to see which one best prevents another heart attack, stroke, or death while also reducing serious bleeding. Participants will either receive a shorter course of dual therapy followed by one drug, or the standard 12-month dual therapy. The goal is to improve long-term outcomes without increasing risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 8,100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2026

Expected to finish

Jan 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ≥18 years old * Admitted because of an acute MI (either STEMI or NSTEMI). * Invasive management during index admission with successful PCI. * Able to consent. Exclusion Criteria: * Indication for oral anticoagulation therapy. * Intolerance, contraindication or known allergy to either aspirin, prasugrel or ticagrelor. * Prior history of ischaemic or haemorrhagic stroke or transient ischaemic attack. * Patients with active bleeding or known bleeding disorders. * Patients with known moderate or severe hepatic dysfunction (Child-Pugh Class B or Class C). * Known intracranial aneurism, arteriovenous malformation or neoplasm. * Patients with chronic kidney disease requiring dialysis. * Any disorder that may interfere with drug absorption. * Pregnancy or current lactation. * Concomitant use of potent CYP3A inhibitors or inducers. * Planned elective surgery that cannot be deferred 12 months before randomization, requiring interruption of antiplatelet therapy. * Any medical condition that, in the investigator´s judgment, would seriously limit life expectancy (less than one year) * Active participation in other clinical trials.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute myocardial infarction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute coronary syndrome acute myocardial infarction Hemorrhage Infarction myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myocardial infarction (MI)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites in 5 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Fundación Jiménez Díaz University Hospital

    RECRUITING

    Madrid, Spain

  • Mater Private Network Dublin

    NOT_YET_RECRUITING

    Dublin, Ireland

  • Oslo University Hospital, Ullevål.

    NOT_YET_RECRUITING

    Oslo, Norway

  • Paula Stradiņa klīniskā universitates slimnīca

    NOT_YET_RECRUITING

    Riga, Latvia

  • Saint John Paul II Hospital in Cracow

    NOT_YET_RECRUITING

    Krakow, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.